Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28061196 | 1.00 | CYP2C19 (0.39) | CYP2C19ALDH1A1SMN1; SMN2TSHRLMNA | |
| Hydrochloric Acid SCHEMBL28070089 | 0.97 | CYP2C19 (0.38) | CYP2C19ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL9032311 | 0.97 | CYP2C19 (0.36) | CYP2C19ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL10332168 | 0.92 | FFAR3 (0.33) | CYP2C19FFAR3ACHE | |
| Acrylic Acid SCHEMBL29199589 | 0.87 | LMNA (0.40) | CYP2C19ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL811779 | 0.86 | TSHR (0.36) | CYP2C19ALDH1A1SMN1; SMN2TSHRLMNA | |
| Cyclohexane SCHEMBL9122052 | 0.86 | TSHR (0.36) | CYP2C19ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL612927 | 0.86 | — | — | |
| Water SCHEMBL7154661 | 0.83 | TSHR (0.35) | CYP2C19ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL518477 | 0.83 | CYP2C19 (0.46) | CYP2C19ALDH1A1SMN1; SMN2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210045983-A1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2021-02-18 | — | — | US | claimed |
| EP-3773445-A1 | RETINOL REPLACEMENT IN SKIN TREATMENT | Symrise AG (DE) | 2021-02-17 | — | — | EP | claimed |
| CN-111918637-A | Retinol substitute in skin treatment | 西姆莱斯有限公司 | 2020-11-10 | — | — | CN | claimed |
| WO-2019185923-A1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2019-10-03 | — | — | WO | claimed |
| US-20180185301-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYALKYLENE GLYCOL DERIVATIVES | SYMRISE AG (DE) | 2018-07-05 | — | — | US | claimed |
| WO-2016207084-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYALKYLENE GLYCOL DERIVATIVES | SYMRISE AG (DE) | 2016-12-29 | — | — | WO | claimed |
| EP-3108941-A1 | COMPOSITIONS COMPRISING POLYALKYLENE GLYCOL DERIVATIVES | Symrise AG (DE) | 2016-12-28 | — | — | EP | claimed |
| EP-2887929-A2 | COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S) | Symrise AG (DE) | 2015-07-01 | — | — | EP | claimed |
| WO-2012143576-A2 | COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S) | SYMRISE AG (DE) | 2012-10-26 | — | — | WO | claimed |
| EP-2168957-B1 | Alkyl-substituted tetrahydropyranes as aromatic materials | SYMRISE AG (DE) | 2012-02-15 | — | — | EP | claimed |
| EP-2416766-A2 | COMPOSITIONS COMPRISING TRANS-TERT-BUTYL CYCLOHEXANOL AS SKIN IRRITATION-REDUCING AGENT | Symrise AG (DE) | 2012-02-15 | — | — | EP | claimed |
| WO-2009087242-A2 | COMPOSITIONS COMPRISING TRANS-TERT-BUTYL CYCLOHEXANOL AS SKIN IRRITATION-REDUCING AGENT | SYMRISE GMBH & CO. KG (DE) | 2009-07-16 | — | — | WO | claimed |
| EP-0337348-A2 | Amides of cyclomethylen-1,2-bicarboxylic acids having therapeutical activity, processes for their preparation and pharmaceutical compositions containing them | Laboratori Guidotti S.p.A. (IT) | 1989-10-18 | — | — | EP | claimed |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | SYMRISE AG (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11801210-B2 | Retinol replacement in skin treatment | SYMRISE AG (DE) | 2023-10-31 | — | — | US | disclosed |
| US-11723850-B2 | Liquid and transparent blend of UV filters | Symrise, AG (DE) | 2023-08-15 | — | — | US | disclosed |
| US-5376674-A | Lipase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5260310-A | Oxetanone compounds and pharmaceutical compositions containing them | HOFFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0444482-A2 | Oxetanones | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-04 | — | — | EP | disclosed |
| EP-0298695-A2 | Tartaric acid amide derivative and method of producing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210045983-A1 | RETINOL REPLACEMENT IN SKIN TREATMENT | RBP1, RBP4, LRAT | CYP2C19 1901/4885ALDH1A1 23/4885SMN1; SMN2 2966/4885 |
| US-11801210-B2 | Retinol replacement in skin treatment | RBP1, RBP4, LRAT | CYP2C19 1728/4885ALDH1A1 22/4885SMN1; SMN2 3314/4885 |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | CUTA, POLR1C, SLC16A7 | CYP2C19 2203/4885ALDH1A1 938/4885SMN1; SMN2 3272/4885 |
| US-11723850-B2 | Liquid and transparent blend of UV filters | F2, F12, F10 | CYP2C19 53/4885ALDH1A1 594/4885SMN1; SMN2 4515/4885 |
| US-20180185301-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYALKYLENE GLYCOL DERIVATIVES | PARG, PARN, TRPV1 | CYP2C19 1381/4885ALDH1A1 3233/4885SMN1; SMN2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.